Plain-English translation of NCT06439992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This trial is testing a new radioactive tracer called [18F]-Fluselenamyl that helps doctors see amyloid plaques in the brain — the protein clumps that are linked to Alzheimer's disease. Researchers will use special brain imaging scans (called PET scans) to see how well this new medication works and compare it to an existing imaging agent. The goal is to develop a better way to detect Alzheimer's disease early, before symptoms become severe.
Current methods for detecting Alzheimer's disease are limited, and doctors need better tools to identify the disease in its early stages. This medication could help create a more effective way to spot amyloid plaques in the brain, potentially allowing treatment to start sooner.
You likely qualify if…
You likely don't qualify if…
You will visit the research center where trained medical professionals will inject you with the radioactive imaging medication through an IV. You will then lie still in a PET scanner while it takes pictures of your brain — this usually takes 30 minutes to an hour. You may also have an MRI scan and blood work. Depending on which group you're in, you might receive both imaging medications to help researchers compare them. The entire study process takes a few hours, and you'll likely have one or two visits.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Sponsor
Washington University School of Medicine
Enrollment target
~60 participants
Started
November 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jayashree Rajamanickam
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.